Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

12/01/2016 - 3 minutes

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections.

nestle_health_science_seres_health_microbiomics_c_difficileBy correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way of treating many chronic gastrointestinal diseases.

In addition to connections with Moderna and Flagship Ventures, Seres has now also entered into an agreement with Nestlé Health Science in Epalinges (Switzerland) for the development and commercialization for its product candidates (SER-109 and SER-262) for Clostridium difficile infections (CDI).

Candidates SER-287 and SER-301 against inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, will also be included in the partnership program.

Nestlé Health Science agreed to provide Seres with an upfront payment of €110.5M ($120M) in cash and a series of development and sales milestones and tiered royalties.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member